Literature DB >> 31494001

Two-dimensional Shear Wave Elastography with Propagation Maps for the Assessment of Liver Fibrosis and Clinically Significant Portal Hypertension in Patients with Chronic Liver Disease: A Prospective Study.

Sun Kyung Jeon1, Jeong Min Lee2, Ijin Joo3, Jeong Hee Yoon3, Dong Ho Lee3, Joon Koo Han4.   

Abstract

OBJECTIVES: To investigate the diagnostic performance of liver stiffness (LS) measurements on two-dimensional (2D) shear wave elastography (SWE) for the assessment of hepatic fibrosis using LS measurements on MR elastography (MRE) as the reference standard and the prediction of clinically significant portal hypertension (CSPH).
METHODS: In this prospective study, 101 patients with chronic liver disease or cirrhosis underwent both MRE and SWE. After exclusion of technical failure on MRE (n = 5), technical failure/unreliable measurement on SWE (n = 4), LS measurements obtained on SWE with the aid of propagation maps were correlated with those of the MRE using Pearson's correlation analysis. Diagnostic performances for significant fibrosis (≥F2: MRE of ≥2.99 kPa) or cirrhosis (F4: MRE of ≥3.63 kPa) and for the prediction of CSPH were assessed using receiver operating characteristics (ROC) curve analysis.
RESULTS: LS values on SWE showed a strong correlation with those on MRE (r = 0.846, P < 0.001). For the diagnosis of significant fibrosis or cirrhosis in patients with hepatitis B virus-related liver disease (n = 75), SWE showed areas under the ROC curves (AUC) of 0.975 and 0.912, respectively (95% confidence interval [CI], 0.910-997, and 0.824-0.965). For the prediction of CSPH, the AUC of SWE was 0.818 (95% CI, 0.712-0.898), and when an LS value of 11.5 kPa was applied as a cut-off, SWE showed a sensitivity of 81.5% and a specificity of 72.9%.
CONCLUSION: LS measurements on 2D SWE were demonstrated to be well correlated with those obtained with MRE, and thus, may provide good diagnostic performance for the prediction of hepatic fibrosis and the presence of CSPH.
Copyright © 2019 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Elastography; Liver fibrosis; Magnetic resonance elastography; Portal hypertension; Sonoelastography

Mesh:

Year:  2019        PMID: 31494001     DOI: 10.1016/j.acra.2019.08.006

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  6 in total

Review 1.  Advances in Magnetic Resonance Elastography of Liver.

Authors:  Jiahui Li; Sudhakar Kundapur Venkatesh; Meng Yin
Journal:  Magn Reson Imaging Clin N Am       Date:  2020-06-06       Impact factor: 2.266

2.  Quality Control of Magnetic Resonance Elastography Using Percent Measurable Liver Volume Estimation.

Authors:  David H Ballard; Daniel R Ludwig; Tyler J Fraum; Amber Salter; Vamsi R Narra; Anup S Shetty
Journal:  J Magn Reson Imaging       Date:  2021-10-27       Impact factor: 5.119

3.  Evaluation of liver fibrosis in chronic hepatitis B patients with 2D shear wave elastography with propagation map guidance: a single-centre study.

Authors:  Seyhmus Kavak; Safak Kaya; Ayhan Senol; Nilgun Sogutcu
Journal:  BMC Med Imaging       Date:  2022-03-18       Impact factor: 1.930

4.  Quantitative Assessment of Portal Hypertension by Two-Dimensional Shear Wave Elastography in Rat Models of Nonalcoholic Fatty Liver Disease: Comparison With Four Composite Scores.

Authors:  Bingtian Dong; Yuping Chen; Guorong Lyu; Yongjian Chen; Ran Qin
Journal:  Front Med (Lausanne)       Date:  2022-03-31

5.  Detection of liver and spleen stiffness in rats with portal hypertension by two-dimensional shear wave elastography.

Authors:  YongJian Chen; JingYun Li; Qin Zhou; GuoRong Lyu; ShiLin Li
Journal:  BMC Med Imaging       Date:  2022-04-13       Impact factor: 1.930

6.  Network Meta-Analysis: Noninvasive Imaging Modalities for Identifying Clinically Significant Portal Hypertension.

Authors:  Yang Hai; Weelic Chong; John R Eisenbrey; Flemming Forsberg
Journal:  Dig Dis Sci       Date:  2021-07-17       Impact factor: 3.487

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.